GlassScriptPhysician profile
Elham Afghani
NPI 1710166095
$12,036.96
in general payments reported to CMS, 2019-2025
22 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,104 · 2021: $1,165 · 2022: $724 · 2023: $509 · 2024: $3,470 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,850 · Food and Beverage: $2,091 · Travel and Lodging: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,850.00 |
| Food and Beverage | $2,091.49 |
| Travel and Lodging | $102.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,413.92 | 2019-2025 | Creon, Linzess, Viberzi |
| Amgen INC. | $3,464.89 | 2024-2025 | Uplizna |
| Nestle Healthcare Nutrition INC. | $875.00 | 2021 | |
| Celgene Corporation | $179.46 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $144.31 | 2025 | Rezdiffra |
| Fujifilm Healthcare Americas Corporation | $142.86 | 2023 | Fujifilm |
| Laborie Medical Technologies Corp. | $136.50 | 2022 | |
| Boston Scientific Corporation | $128.75 | 2022 | |
| Qol Medical, LLC | $101.72 | 2019-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.33 | 2019-2024 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $72.05 | 2023-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $46.25 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $39.39 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $30.05 | 2023 | |
| Digestive Care, INC. | $25.48 | 2025 | Pertzye |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $25.34 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $23.13 | 2024 | Dupixent |
| Lilly USA, LLC | $22.06 | 2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $19.81 | 2023 | Gattex |
| Concordia Pharmaceuticals INC. | $18.86 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.76 | 2025 | Givlaari |
| Abbott Laboratories | $17.04 | 2023 | Xience Sierra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elham Afghani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.